Breaking News Instant updates and real-time market news.

YUMC

Yum China

, CAPR

Capricor Therapeutics

$2.81

-0.31 (-9.94%)

09:25
10/06/17
10/06
09:25
10/06/17
09:25

On The Fly: Pre-market Movers

HIGHER: Yum China (YUMC), up 1.9% after reporting quarterly results... Capricor Therapeutics (CAPR), up 27.4% after providing data which supports the peripheral intravenous administration method the company plans to use in HOPE-2, its planned next clinical trial of its lead investigational product, CAP-1002, for the treatment of Duchenne muscular dystrophy... Synchronoss (SNCR), up 27% after entering into an exclusivity agreement with Siris Capital to allow for negotiation of definitive agreements... Herbalife (HLF), up marginally after announcing preliminary results of its modified Dutch auction tender. DOWN AFTER EARNINGS: Costco (COST), down 5.1%... Eros International (EROS), down 1.6%. ALSO LOWER: Annaly Capital (NLY), down 2.8% after its 65M share Spot Secondary priced at $12.00.

YUMC

Yum China

CAPR

Capricor Therapeutics

$2.81

-0.31 (-9.94%)

SNCR

Synchronoss

$10.72

-0.01 (-0.09%)

HLF

Herbalife

COST

Costco

$167.07

1.86 (1.13%)

EROS

Eros International

NLY

Annaly Capital

  • 06

    Oct

  • 19

    Oct

  • 02

    Nov

  • 06

    Oct

YUMC Yum China

09/21/17
SBSH
09/21/17
INITIATION
Target $51
SBSH
Buy
Yum China initiated with a Buy at Citi (Monday)
Citi analyst Xiaopo Wei on Monday started Yum China with a Buy rating and $51 price target. With over 2B annual customer visits to its restaurants, the company "has very few equals as a play on China consumption," Wei told investors in a research note.
07/12/17
MSCO
07/12/17
NO CHANGE
Target $41
MSCO
Overweight
Morgan Stanley remains bullish on Yum China
Yum China analyst John Glass said he remains bullish on Yum China following the Q2 "exaggerated" selloff. The analyst said the shares were week due to strong share performance since the Q1 report, a mixed shareholder base, high comp expectations, and vague second half margin guidance. Glass remains optimistic and reiterated his Overweight rating and $41 price target on Yum China given expectations KFC comps can accelerate further in the second half, margin expansion, and said long-term margin goal of 17% appears conservative.
07/06/17
07/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) downgraded to Sector Perform from Outperform at RBC Capital with analyst Biraj Borkhataria saying Exxon's differentiated downstream positioning generates a significant portion of its free cash flow, but it is reflected in valuation. 2. O'Reilly Automotive (ORLY) downgraded to Neutral from Outperform at Credit Suisse and to Equal Weight from Overweight at Morgan Stanley. 3. Norfolk Southern (NSC) downgraded to Sector Perform from Outperform at Scotiabank. 4. Yum China (YUMC) downgraded to Hold from Buy at Deutsche Bank with analyst Anne Ling citing the company's second quarter results. 5. Tahoe Resources (TAHO) downgraded to Market Perform from Outperform at BMO Capital and to Hold from Buy at TD Securities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/06/17
DBAB
07/06/17
DOWNGRADE
Target $36.61
DBAB
Hold
Yum China downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Anne Ling downgraded Yum China to Hold with a $36.61 price target following the company's Q2 results.
CAPR Capricor Therapeutics
$2.81

-0.31 (-9.94%)

07/18/17
RODM
07/18/17
NO CHANGE
Target $2.15
RODM
Buy
FDA decision encouraging for Capricor Duchenne drug, says Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis notes that Capricor Therapeutics' CAP-1002 took an important regulatory step forward with the FDA granting Rare Pediatric Disease Designation for Duchenne muscular dystrophy. Should the positive CAP-1002 data continue to be positive and the therapy approved, Capricor could also be eligible for a Priority Review Voucher, or PRV, the analyst points out, adding that a key potential outcome to a PRV is not only an accelerated path to market, but the ability to sell the PRV for significant non-dilutive funding. Pantginis reiterates a Buy rating and $2.15 price target on the shares. In late morning trading, Capricor Therapeutics' stock has more than doubled to $1.44.
09/15/17
HCWC
09/15/17
NO CHANGE
Target $6.5
HCWC
Buy
Capricor Therapeutics price target raised to $6.50 from $2.15 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target Capricor Therapeutics to $6.50 after increasing his projected chance of success for CAP-1002 in Duchenne muscular dystrophy to 15% from 5%. The analyst sees "significant" FDA visibility for the company's DMD program and believe catalysts next quarter could "reinvigorate interest in the shares." He keeps a Buy rating on Capricor.
02/13/17
RODM
02/13/17
INITIATION
Target $14
RODM
Buy
Capricor Therapeutics assumed with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis assumed coverage of Capricor Therapeutics with a Buy rating and $14 price target. The analyst believes the company has the potential to be a leader in cardiovascular regenerative medicine.
SNCR Synchronoss
$10.72

-0.01 (-0.09%)

09/19/17
09/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Market Perform at Wells Fargo with Wells Fargo with analyst Tom Nikic saying with consumers having filled their closets with athletic wear over the past seven years, the category "appears poised to take a breather for now." The analyst cut his price target for the shares to $13 from $17. 2. Kellogg (K) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Lavery saying cereal could be at risk from shrinking center store space. 3. Nike (NKE) downgraded to Neutral from Positive at Susquehanna saying that his checks indicate that the North American and European businesses are decelerating as some key categories, especially basketball, have underperformed, resulting in excess inventory that will pressure sales and margins. 4. Synchronoss (SNCR) downgraded to Underperform from Outperform at Raymond James with analyst Tavis McCourt citing the news that Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest. 5. Sony (SNE) downgraded to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/17
DBAB
09/20/17
NO CHANGE
Target $10
DBAB
Hold
Synchronoss price target lowered to $10 from $18 at Deutsche Bank
Deutsche Bank analyst Nandan Amladi cut his price target for Synchronoss Technologies to $10 citing increased uncertainty after Siris Capital decided not to pursue an all-cash acquisition of the company. Yesterday's 40% selloff retraces the pre-offer levels in June, Amladi tells investors in a research note. He continues to believe an eventual transaction "provides a clean exit" for Synchronoss shareholders, given the "mounting complications" facing the company. The analyst keeps a Hold rating on the shares.
06/22/17
JPMS
06/22/17
NO CHANGE
JPMS
Neutral
Synchronoss comments on carriers should help ease concerns, says JPMorgan
JPMorgan analyst Sterling Auty said that comments made by Synchronoss (SNCR) in a presentation to its lenders regarding AT&T (T) and Verizon (VZ) continuing to be cloud customers should help ease some of the concern investors have had around the company's cloud business. Auty keeps a Neutral rating on Synchronoss shares.
09/19/17
RAJA
09/19/17
DOWNGRADE
RAJA
Underperform
Synchronoss downgraded to Underperform from Outperform at Raymond James
Raymond James analyst Tavis McCourt downgraded Synchronoss (SNCR) two notches to Underperform from Outperform following news Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest.
HLF Herbalife

10/03/17
PIVT
10/03/17
NO CHANGE
Target $120
PIVT
Buy
Herbalife estimates lowered on share repurchase challenges at Pivotal Research
Pivotal analyst Timothy Ramey lowered his Q4 and 2018 estimates for Herbalife as he now believes the company's and his own share repurchase forecasts "are not attainable." Ramey added that "is bizarre that the company was so singularly unsuccessful at share repurchase to not even spend its cash flow this year," but he hopes the company's Dutch Auction is successful and allows for some progress on retiring shares. He keeps a Buy rating and $120 price target on Herbalife shares.
10/03/17
SBSH
10/03/17
NO CHANGE
Target $73
SBSH
Neutral
Citi still cautious on Herbalife after updated Q3 outlook
Citi analyst Beth Kite says Herbalife's initial Q3 guidance offered sales growth as expected and higher earnings on a lower tax rate. The analyst notes her investment thesis remains focused on local currency sales growth. As such, last night's updated guidance keeps unchanged Kite's "cautious position on the shares." She raised her price target for Herbalife to $73 from $71 and keeps a Neutral rating on the name.
08/03/17
TIGR
08/03/17
NO CHANGE
TIGR
Buy
Herbalife's 2017 remains a transition year, says Tigress Financial
In a post-earnings research note, Tigress Financial analyst Ivan Feinseth believes 2017 remains a transition year for Herbalife. He expects the company's business to show positive acceleration as management continues to implement new initiatives to drive growth. He reiterates a Buy rating on the shares.
08/02/17
SBSH
08/02/17
NO CHANGE
Target $72
SBSH
Neutral
Herbalife earnings beat on lower tax rate, says Citi
Citi analyst Beth Kite attributes Herbalife's better than expected Q2 earnings to a lower tax rate. The analyst raised her 2017 earnings per share estimate to $4.70 from $4.62 but lowered her 2018 estimate to $4.98 from $5.15. Kite has concerns over the impact of the FTC Consent Order in the U.S., Nutrition Club dynamics and social media pressures in China as well as the distributor sponsorship in Mexico. She lowered her price target for Herbalife shares to $72 from $74 and keeps a Neutral rating on the shares.
COST Costco
$167.07

1.86 (1.13%)

10/06/17
BARD
10/06/17
NO CHANGE
Target $200
BARD
Outperform
Any post-earnings pullback in Costco provides a buying opportunity, says Baird
Baird analyst Peter Benedict noted Costco reported better than expected Q4 earnings and said it remains a compelling growth staple idea with its healthy fundamentals and an improved valuation profile. The analyst said any pullback in Costco share would be a good buying opportunity and shares look attractive at current levels. Benedict reiterated his Outperform rating and $200 price target on Costco shares.
10/06/17
RBCM
10/06/17
NO CHANGE
Target $190
RBCM
Outperform
Costco has some of the best traffic growth in retail, says RBC Capital
RBC Capital analyst Scot Ciccarelli said Costco reported better than expected Q4 results as total comps increased 5.7% versus his 5.3% estimate and consensus of 5.1%, while gross margin pressures were largely offset by expense leverage. Despite investors fears regarding risk from e-commerce, the analyst said Costco continues to have some of the best traffic growth in retail and is gaining traction from its own e-commerce initiates. Ciccarelli said he remains a buyer of Costo and increased his price target on shares to $190 from $184 and reiterated his Outperform rating on shares.
10/06/17
MSCO
10/06/17
DOWNGRADE
MSCO
Equal Weight
Costco downgraded to Equal Weight from Overweight at Morgan Stanley
10/06/17
10/06/17
DOWNGRADE
Target $165

Equal Weight
Costco downgraded on EPS growth slowdown at Morgan Stanley
As previously reported, Morgan Stanley analyst Simeon Gutman downgraded Costco to Equal Weight from Overweight, stating that after its Q4 report last night he has cut his FY18 EPS growth estimate to $6.30. Moderating membership growth also led him to lower his EBITDA multiples, said Gutman, who added that the combination of decelerating EPS growth and "membership slippage" may make it tough for the stock to outperform. Gutman lowered his price target to $165 from $190 on Costco shares, which are down 4.5% to $159.50 in pre-market trading following last night's quarterly report.
EROS Eros International

12/09/16
WELS
12/09/16
UPGRADE
WELS
Outperform
Eros International upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Eric Katz upgraded Eros International to Outperform citing more confidence in the name after news yesterday that ErosNow hit 2M paid subscribers two quarters ahead of schedule. The company's new business-to-business model is working, Katz tells investors in a research note. He raised his price target range for the shares to $18-$20 from $16-$18.
08/07/17
WELS
08/07/17
NO CHANGE
WELS
Outperform
Eros library sale and reverse merger both make sense, says Wells Fargo
Wells Fargo analyst Eric Katz noted that media reports indicate Eros (EROS) is said to be in talks to possibly sell its library of film rights, and possibly its over-the-top streaming service, to Apple (AAPL), Amazon (AMZN) or Netflix (NFLX). A media report also claims the company could be looking to "reverse merge" its NYSE-listed entity into is Indian-listed subsidiary. Both moves would make sense, said Katz, who keeps an Outperform rating on Eros share, which are up 23% to $10.10 in early trading.
NLY Annaly Capital

12/20/16
FBRC
12/20/16
DOWNGRADE
Target $10
FBRC
Market Perform
Annaly Capital downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Jessica Levi-Ribner downgraded Annaly Capital to Market Perform saying a discount to book is appropriate given her expectation for fixed-income market volatility and rising rates in FY17. The analyst lowered her price target for the shares to $10 from $12.
12/15/16
BOFA
12/15/16
DOWNGRADE
Target $9
BOFA
Neutral
Annaly Capital downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Kenneth Bruce downgraded Annaly Capital to Underperform and lowered its price target to $9 from $11. The analyst sees risk to mortgage related stocks in a rising rate environment with increased volatility as rate sensitive assets erode book value and a flatter yield cure pressures earnings. The firm believes deflation has peaked, and the expected unwind will result in sector rotation out of bonds.

TODAY'S FREE FLY STORIES

TXN

Texas Instruments

$95.18

1.73 (1.85%)

13:10
10/23/17
10/23
13:10
10/23/17
13:10
Options
Texas Instruments calls active as shares see relative strength ahead of earnings »

Texas Instruments calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

EEFT

Euronet

$98.71

1.93 (1.99%)

13:09
10/23/17
10/23
13:09
10/23/17
13:09
Conference/Events
Euronet management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Dec

NVS

Novartis

$86.19

0.45 (0.52%)

, MCD

McDonald's

$164.22

-2.08 (-1.25%)

13:06
10/23/17
10/23
13:06
10/23/17
13:06
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$86.19

0.45 (0.52%)

MCD

McDonald's

$164.22

-2.08 (-1.25%)

MMM

3M

$222.12

0.8 (0.36%)

UTX

United Technologies

$120.63

-0.3 (-0.25%)

LLY

Eli Lilly

$87.68

0.45 (0.52%)

LMT

Lockheed Martin

$320.44

0.44 (0.14%)

CAT

Caterpillar

$132.06

0.7 (0.53%)

BIIB

Biogen

$338.10

-4.32 (-1.26%)

GM

General Motors

$45.37

-0.2389 (-0.52%)

SHW

Sherwin-Williams

$389.65

-0.055 (-0.01%)

INFY

Infosys

$14.90

0.34 (2.34%)

GLW

Corning

$30.36

0.295 (0.98%)

PCAR

Paccar

$74.92

1.15 (1.56%)

SWK

Stanley Black & Decker

$159.75

-0.37 (-0.23%)

FITB

Fifth Third

$28.60

0.32 (1.13%)

CNC

Centene

$97.59

1.09 (1.13%)

WAT

Waters

$188.63

0.49 (0.26%)

IPG

Interpublic Group

$20.62

-0.2641 (-1.26%)

WAB

Wabtec

$76.28

-0.59 (-0.77%)

HUBB

Hubbell

$121.43

-1.6355 (-1.33%)

JBLU

JetBlue

$20.35

0.01 (0.05%)

PII

Polaris Industries

$106.55

0.09 (0.08%)

GPK

Graphic Packaging

$14.30

0.02 (0.14%)

R

Ryder

$82.98

-0.67 (-0.80%)

CVLT

Commvault

$58.55

0.5 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 07

    Dec

  • 17

    May

WHR

Whirlpool

$182.85

0.39 (0.21%)

, ARNC

Arconic

$25.05

-2.12 (-7.80%)

13:05
10/23/17
10/23
13:05
10/23/17
13:05
Earnings
Notable companies reporting after market close »

Notable companies…

WHR

Whirlpool

$182.85

0.39 (0.21%)

ARNC

Arconic

$25.05

-2.12 (-7.80%)

ZION

Zions Bancorp

$46.76

0.71 (1.54%)

CR

Crane

$84.02

-0.09 (-0.11%)

OI

Owens-Illinois

$25.35

-0.24 (-0.94%)

RMBS

Rambus

$13.70

0.12 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 14

    Nov

  • 07

    Dec

COG

Cabot Oil & Gas

$25.39

-0.14 (-0.55%)

13:05
10/23/17
10/23
13:05
10/23/17
13:05
Options
Cabot Oil & Gas call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

13:05
10/23/17
10/23
13:05
10/23/17
13:05
General news
Treasury Action: the markets are quiet as a wait and see stance prevails »

Treasury Action: the…

NKE

Nike

$53.79

0.73 (1.38%)

12:55
10/23/17
10/23
12:55
10/23/17
12:55
Options
Nike put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ADP

ADP

$115.93

1.31 (1.14%)

12:54
10/23/17
10/23
12:54
10/23/17
12:54
Hot Stocks
ADP 'strongly disagrees' with Glass Lewis' recommendation on director election »

ADP issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

UTX

United Technologies

$120.73

-0.205 (-0.17%)

12:46
10/23/17
10/23
12:46
10/23/17
12:46
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend ahead of news »

Shares have been trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FCX

Freeport McMoRan

$14.78

-0.049 (-0.33%)

12:45
10/23/17
10/23
12:45
10/23/17
12:45
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

AGN

Allergan

$189.61

1.33 (0.71%)

12:45
10/23/17
10/23
12:45
10/23/17
12:45
Periodicals
Allergan has weak balance sheet after large buybacks, WSJ's Grant says »

Allergan squandered the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

  • 01

    Nov

  • 06

    Nov

SSYS

Stratasys

$23.21

2.26 (10.79%)

12:37
10/23/17
10/23
12:37
10/23/17
12:37
Hot Stocks
Stratasys announces NYU study on treating kidney issues with 3D technology »

Stratasys announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

TAL

TAL Education

$34.05

-0.865 (-2.48%)

12:35
10/23/17
10/23
12:35
10/23/17
12:35
Options
Tal Education Group put volume heavy and directionally bearish »

Bearish flow noted in Tal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

LGL

LGL Group

$5.66

0.1 (1.80%)

12:32
10/23/17
10/23
12:32
10/23/17
12:32
Hot Stocks
LGL Group reports extension of rights offering expiration to November 13 »

The LGL Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBW

Build-A-Bear

$8.15

-0.1 (-1.21%)

12:32
10/23/17
10/23
12:32
10/23/17
12:32
Conference/Events
Build-A-Bear management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

SYBX

Synlogic

$15.01

-1.46 (-8.86%)

12:28
10/23/17
10/23
12:28
10/23/17
12:28
Conference/Events
Synlogic management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ROIC

Retail Opportunity

$18.76

-0.3 (-1.57%)

12:26
10/23/17
10/23
12:26
10/23/17
12:26
Conference/Events
Retail Opportunity management to meet with Jefferies »

Meetings to be held n…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

MCD

McDonald's

$164.42

-1.88 (-1.13%)

12:26
10/23/17
10/23
12:26
10/23/17
12:26
Technical Analysis
Technical Earnings Preview: McDonald's testing support ahead of earnings »

Price has been within a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

XOM

Exxon Mobil

$83.21

0.1 (0.12%)

12:20
10/23/17
10/23
12:20
10/23/17
12:20
Options
11.7K Exxon Mobile Jan 82.5 - Mar 87.5 call spreads bought for $1.40 »

11.7K Exxon Mobile Jan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

$NSD

NASDAQ Market Internals

12:17
10/23/17
10/23
12:17
10/23/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
10/23/17
10/23
12:16
10/23/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
10/23/17
10/23
12:15
10/23/17
12:15
General news
Treasury Option Action: some "call fly" demand »

Treasury Option Action:…

SAGE

Sage Therapeutics

$63.50

0.58 (0.92%)

12:10
10/23/17
10/23
12:10
10/23/17
12:10
Options
Sizable ratio spread in Sage Therapeutics »

Sizable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$35.00

-0.25 (-0.71%)

12:08
10/23/17
10/23
12:08
10/23/17
12:08
Periodicals
Volkswagen receives approval from U.S regulators for SUV fix, Reuters says »

U.S and California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBS

Rambus

$13.70

0.12 (0.88%)

12:05
10/23/17
10/23
12:05
10/23/17
12:05
Technical Analysis
Technical Earnings Preview: Rambus in bullish price channel ahead of news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.